Global private equity investment in healthcare closed 2025 at $191 billion in aggregate deal value, surpassing the $185 billion posted in 2021, according to Bain & Company's annual sector report. The figure marks the first time healthcare PE has exceeded the SPAC-era highs, when zero-rate capital flooded quality-agnostic targets. This time, the capital went to revenue-stage platforms with regulatory moats.
The 2025 tally represents a 3.2 percent increase over 2021, but the deal count fell 17 percent year-over-year, per Bain. Median check sizes rose to $240 million, up from $175 million in 2023, as allocators bypassed sub-scale assets and moved directly into carve-outs and add-on rolls within physician practice management, specialty pharma distribution, and device servicing. Mega-deals above $1 billion accounted for 41 percent of total value, the highest concentration since 2019. Dry powder earmarked for healthcare sits at $127 billion across 340 funds, a 22 percent increase from the prior year.
This matters because the capital is now structurally anchored in care delivery rather than speculative diagnostics or telehealth platforms that evaporated post-2022. Allocators are betting on aging demographics, Medicare Advantage penetration crossing 55 percent of eligible lives, and continued regulatory capture in high-margin subspecialties like dermatology, ophthalmology, and pain management. The shift to value-based care models has turned physician groups into reliable EBITDA generators with 18-month payback windows on bolt-ons, making them more attractive than software plays with uncertain retention curves. Meanwhile, the Federal Trade Commission has opened 14 Hart-Scott-Rodino reviews on healthcare roll-ups in the past 18 months, a 40 percent uptick, signaling increased scrutiny on horizontal integration. None have been blocked outright, but letters of concern are extending close timelines by 90 to 120 days.
The strategic question is whether this cycle sustains or whether we are in the final innings of regulatory arbitrage before Washington tightens oversight on PE-backed care platforms. Observers should track Q1 2026 FTC enforcement actions, CMS rulemaking on ASC reimbursement, and whether distribution to LPs from healthcare funds in vintage years 2018-2020 continues to outpace peer categories, which would pull incremental allocations forward.
The next catalyst arrives in March 2026, when Bain releases its physician practice management sub-sector analysis, expected to show $47 billion in standalone transaction value and reveal which specialties absorbed the most capital.